Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis

Wang, Quan; Ji, Xiaoquan; Sun, Jing; Li, Wengang; Duan, Xiaojiang; Zhang, Aimin

doi:10.1007/s00432-023-04652-y

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, small molecule TKIs were added to various locoregional therapy (LRT) modalities including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and stereotactic body radiotherapy (SBRT) for the treatment of HCC. It has been documented that lenvatinib plus TACE [ 121 ], HAIC [ 122 ], or SBRT [ 123 , 124 ], sorafenib plus HAIC [ 125 ] or SBRT [ 126 ], and apatinib [ 127 ], anlotinib [ 128 ], axitinib [ 129 ], or sunitinib [ 130 ] plus TACE improved the survival outcomes of HCC patients compared with lenvatinib [ 121 , 123 ], sorafenib [ 125 ], TACE [ 122 , 127 , 128 , 130 ], or SBRT [ 124 , 126 ] alone. These results remain to be confirmed by large-scale randomized controlled trials (RCTs).…”

Section: Future Perspectivesmentioning

confidence: 99%

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Liu,

Xia,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of liver cancer. More than half of the HCC patients are diagnosed at an advanced stage and often require systemic therapy. Dysregulation of the activity of receptor tyrosine kinases (RTKs) is involved in the development and progress of HCC, RTKs are therefore the potential targets for systemic therapy of advanced HCC (aHCC). Currently, a total of six small molecule tyrosine kinase inhibitors (TKIs) have been approved for aHCC, including first-line sorafenib, lenvatinib, and donafenib, and second-line regorafenib, cabozantinib, and apatinib. These TKIs improved patients survival, which are associated with disease stage, etiology, liver function, tumor burden, baseline levels of alpha-fetoprotein, and treatment history. This review focuses on the clinical outcomes of these TKIs in key clinical trials, retrospective and real-world studies and discusses the future perspectives of TKIs for aHCC, with an aim to provide up-to-date evidence for decision-making in the treatment of aHCC.

show abstract